Literature DB >> 10088547

Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach.

A H Ormsby1, J R Goldblum, T W Rice, J E Richter, G W Falk, M F Vaezi, T L Gramlich.   

Abstract

The histological distinction between intestinal metaplasia involving the distal esophagus (Barrett's esophagus [BE]) and intestinal metaplasia of the stomach has important clinical implications and can be difficult even with the use of histochemical mucin stains. Cytokeratin (CK) 7 and 20 are cytoplasmic structural proteins that show restricted expression in normal and malignant epithelia of the gastrointestinal tract. The aim of this study was to determine the use of CK7 and 20 expression in the histological distinction of BE from gastric intestinal metaplasia. CK7 and 20 immunostaining was performed on randomly selected surgical resection (n = 31) and biopsy specimens (n = 34) from patients with long-segment BE and gastric resection specimens (n = 11) and gastric cardia biopsy specimens (n = 13) in patients with histological evidence of intestinal metaplasia. A unique pattern of immunoreactivity designated the Barrett's CK7/20 pattern showed superficial CK20 staining and strong CK7 staining of both superficial and deep glands in 29 of 31 (94%) esophageal resection specimens and 34 of 34 (100%) esophageal biopsy specimens form patients with long-segment BE. A Barrett's CK7/20 pattern was not observed in gastric cardia biopsy specimens (n = 13) or gastric resection specimens (n = 11) in patients with histological evidence of intestinal metaplasia. The sensitivity, specificity, and positive predictive value of a Barrett's CK7/20 pattern for a diagnosis of long-segment BE was 97%, 100%, and 100%, respectively. CK7 and 20 reactivity patterns can reliably identify the location of intestinal metaplasia in the esophagus and stomach using histological material from both routine endoscopic biopsy and surgical resection specimens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10088547     DOI: 10.1016/s0046-8177(99)90007-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  30 in total

1.  Cytokeratin immunoreactivity of intestinal metaplasia.

Authors:  I A Mouzas; I Jovanovic; T Milosavljevic; M Tzardi; P Kanavaros
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 2.  Cancer of the esophagogastric junction: epidemiology and pathogenesis.

Authors:  Prateek Sharma
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

Review 3.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 4.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

5.  A "crackleware" oesophagus.

Authors:  M Westerterp; O R C Busch; J J G H M Bergman; F J W Ten Kate; J J B van Lanschot
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

6.  On the origin of cardiac mucosa: a histological and immunohistochemical study of cytokeratin expression patterns in the developing esophagogastric junction region and stomach.

Authors:  Gert De Hertogh; Peter Van Eyken; Nadine Ectors; Karel Geboes
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

7.  Signet-ring cell carcinoma of the esophagus associated with Barrett's epithelium: report of a case.

Authors:  Kiichi Maezato; Tadashi Nishimaki; Mariko Oshiro; Toshimitu Yamashiro; Hideaki Sasaki; Yasunori Sashida
Journal:  Surg Today       Date:  2007-11-26       Impact factor: 2.549

8.  Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics.

Authors:  Jerzy Ostrowski; Michal Mikula; Jakub Karczmarski; Tymon Rubel; Lucjan S Wyrwicz; Piotr Bragoszewski; Pawel Gaj; Michal Dadlez; Eugeniusz Butruk; Jaroslaw Regula
Journal:  J Mol Med (Berl)       Date:  2007-03-30       Impact factor: 4.599

Review 9.  Barrett's oesophagus: from metaplasia to dysplasia and cancer.

Authors:  J-F Fléjou
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

10.  A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.

Authors:  Rebecca J Critchley-Thorne; Lucas C Duits; Jeffrey W Prichard; Jon M Davison; Blair A Jobe; Bruce B Campbell; Yi Zhang; Kathleen A Repa; Lia M Reese; Jinhong Li; David L Diehl; Nirag C Jhala; Gregory Ginsberg; Maureen DeMarshall; Tyler Foxwell; Ali H Zaidi; D Lansing Taylor; Anil K Rustgi; Jacques J G H M Bergman; Gary W Falk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-13       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.